{"product_id":"immunocore-business-model-canvas","title":"Immunocore Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Model Canvas for an Emerging Immunotherapy Innovator\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Immunocore's strategic blueprint with a concise Business Model Canvas that maps its value propositions, customer segments, and competitive advantages.\u003c\/p\u003e\n\u003cp\u003eThis in-depth canvas highlights revenue streams, key partnerships, and cost structure—ideal for investors, consultants, and founders seeking actionable insights.\u003c\/p\u003e\n\u003cp\u003ePurchase the full Word and Excel-ready canvas to get section-by-section analysis and templates you can use for benchmarking and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology academic centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with leading cancer centers provide access to uveal melanoma and solid tumor cohorts for trials and expert input on TCR targets and clinical endpoints. Joint publications and real-world evidence bolster regulator and payer credibility—exemplified by tebentafusp (KIMMTRAK) trials showing OS HR 0.51 and 1‑year OS 73% vs 59%. These centers also accelerate enrollment and translational insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital networks \u0026amp; KOLs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with melanoma specialists and key opinion leaders drive adoption of KIMMTRAK in eligible patients; FDA approval was granted in 2022 for HLA-A*02:01–positive metastatic uveal melanoma, a genotype present in roughly 40% of patients. Co-developing treatment pathways and referral protocols streamlines access and patient identification. KOL advocacy supports guideline inclusion and payer negotiations, while ongoing clinical feedback informs label-expansion strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialized contract manufacturers support complex biologics production and fill-finish for Immunocore, providing scalable capacity, robust quality systems and global GMP compliance. Engaging 2–3 CDMO partners creates redundancy that reduces supply risk and cost volatility. Tech-transfer agreements lock in consistent ImmTAC yields and process control across sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulators \u0026amp; HTA bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly scientific advice from FDA, EMA and MHRA—following tebentafusp approvals by FDA and EMA in 2022—de-risks Immunocore programs and accelerates trial design; coordinated input from NICE and IQWiG shapes value dossiers and outcome metrics. Post-marketing RWE commitments and data-sharing sustain reimbursement and enable label expansions and new indications.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory approvals: FDA \u0026amp; EMA 2022\u003c\/li\u003e\n\u003cli\u003eHTA engagement: NICE, IQWiG\u003c\/li\u003e\n\u003cli\u003eRWE: supports post‑marketing access\u003c\/li\u003e\n\u003cli\u003eOutcome: enables label expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic \u0026amp; data partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompanion diagnostic collaborators support HLA typing and patient selection, enabling enrollment for HLA-restricted TCRs; HLA-A*02:01 occurs in ~40% of European-ancestry populations (2024). Data platforms enable evidence generation, safety monitoring and outcomes tracking. EHR interoperability improves real‑time identification of eligible patients; US hospital EHR adoption exceeds 96% (2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHLA typing partners\u003c\/li\u003e\n\u003cli\u003eData platforms: safety \u0026amp; outcomes\u003c\/li\u003e\n\u003cli\u003eEHR integration for eligibility\u003c\/li\u003e\n\u003cli\u003eInsights to refine TCR epitope targeting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCenter partnerships drive uptake; OS HR \u003cstrong\u003e0.51\u003c\/strong\u003e, 1yr \u003cstrong\u003e73%\/59%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore partners with leading cancer centers and KOLs to drive tebentafusp adoption (OS HR 0.51; 1‑yr OS 73% vs 59%), with FDA\/EMA approvals in 2022. CDMO network (2–3 partners) secures GMP supply; companion diagnostics enable HLA-A*02:01 (~40%) patient selection. EHR\/data integrations (US EHR adoption 96% in 2024) support enrollment and RWE generation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eFDA\/EMA 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003eOS HR 0.51; 1‑yr OS 73% vs 59%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003eHLA-A*02:01 ~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT\u003c\/td\u003e\n\u003ctd\u003eEHR adoption 96% (US, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e2–3 CDMOs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Immunocore, organized into the 9 classic BMC blocks and tailored to its TCR‑bispecific immunotherapy strategy; covers customer segments, channels, value propositions, revenue streams, key partners\/activities, competitive advantages and linked SWOT insights—designed for presentations, investor discussions and strategic decision‑making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Immunocore’s business model with editable cells—quickly pinpoint how its TCR-T platform, strategic partnerships, and revenue streams alleviate R\u0026amp;D, regulatory, and commercialization pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmTAC R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery and optimization of TCR bispecific ImmTACs targeting tumor-associated antigens, refining TCR affinity and specificity to picomolar ranges. Preclinical validation includes in vitro specificity panels, functional potency assays and GLP toxicology to assess off-target safety. IND-enabling CMC and safety studies advance candidates into the clinic while continuous platform engineering improves potency and persistence; as of 2024 tebentafusp remains the only approved ImmTAC.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and execution of Phase 1–3 trials across solid tumors and infectious diseases, leveraging tebentafusp development experience with regulatory approvals in US and EU in 2022. Site selection, patient recruitment and HLA\/biomarker-driven stratification underpin enrollment efficiency. Safety, efficacy and PK\/PD data packages support filings and label maintenance. Post-approval studies expand indications and inform label updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePreparation of global submissions, regulatory responses and risk-management plans centers on KIMMTRAK, approved by the FDA in 2022 with a pivotal phase III demonstrating overall survival benefit; ongoing filings target EU and Japan. HEOR programs quantify quality-adjusted life-years and budget impact versus standard of care to support value claims. Pricing, reimbursement and tender negotiations focus on payer demonstrations of survival and cost-effectiveness. Lifecycle management pursues label expansions and combination studies to broaden access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBiologics manufacturing for ImmTACs focuses on process development, scale-up from bench to 2,000 L bioreactors, and strict quality control to meet GMP; 2024 industry benchmarks target \u0026gt;30% yield improvements and 20% COGS reduction through optimization. Supply chain orchestration covers raw materials to finished drug product with ~95% on-time delivery, cold-chain logistics at -20 to -80°C to treatment centers, and continuous improvement programs. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProcess dev \u0026amp; scale-up\u003c\/li\u003e\n\u003cli\u003eGMP QC \u0026amp; release testing\u003c\/li\u003e\n\u003cli\u003eSupply chain orchestration\u003c\/li\u003e\n\u003cli\u003eCold-chain -20 to -80°C\u003c\/li\u003e\n\u003cli\u003eYield \u0026amp; COGS optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical \u0026amp; commercial\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical education to oncologists and care teams on KIMMTRAK use leverages the pivotal 2021 NEJM data and 2024 post‑launch studies; field force engagement and account management focus on high‑volume melanoma centers and HLA‑A*02:01 patients (~45% prevalence in Caucasian populations). Real‑world evidence capture and publication strategy support label extension and market access; patient support programs offer financial assistance and hub services to reduce access barriers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedical education: NEJM 2021 pivotal data, ongoing 2024 studies\u003c\/li\u003e\n\u003cli\u003eField force: targeted account management at melanoma centers\u003c\/li\u003e\n\u003cli\u003eRWE: capture, analyze, publish to support reimbursement\u003c\/li\u003e\n\u003cli\u003ePatient support: financial aid and hub coordination to improve uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePicomolar ImmTAC optimization fuels IND\/clinic and GMP scale-up with \u003cstrong\u003e+30%\u003c\/strong\u003e yield\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscovery\/optimization of picomolar TCR‑bispecific ImmTACs; tebentafusp remains sole approved ImmTAC (FDA 2022). IND‑enabling GLP tox, CMC and Phase 1–3 trials (NEJM 2021 pivotal) drive filings and label expansions. GMP scale‑up to 2,000 L bioreactors targets \u0026gt;30% yield gain and 20% COGS cut; 95% on‑time supply and HLA‑A*02:01 ~45% prevalence guide commercial efforts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003ePicomolar affinity; 1 approved ImmTAC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003ePhase 1–3; NEJM 2021 pivotal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e2,000 L; +30% yield; −20% COGS; 95% OTIF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Immunocore Business Model Canvas you see here is the actual deliverable, not a mockup. When you purchase, you'll receive this exact file with all sections included, fully editable and formatted. No placeholders, no extras—just the complete Canvas ready for use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161377321337,"sku":"immunocore-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/immunocore-business-model-canvas.png?v=1762691540","url":"https:\/\/portersfiveforce.com\/products\/immunocore-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}